The efficacy of conventional platinum-based chemotherapy for high-grade serous carcinoma is limited; most patients show an initial response to treatment but upon CCR-10-1382 Olaparib in ovarian cancer xenograft model Research.
BRCA deficiency associated with high grade serous ovarian carcinoma (HGSC), the most frequent histologic subtype in epithelial ovarian cancer (EOC) (3, 4) . Patients with BRCA germline mutations treated with platinum-based therapy regimens have a survival advantage compared to non-hereditary EOC of HGSC subtype (5) . Regardless, the majority of patients with HGSC relapse and ultimately die from their disease, therefore development of effective first line therapies is critical.
BRCA1 and BRCA2 encode tumor suppressor proteins that are part of a multicomponent complex (RAD51 complex) involved in the repair of DNA double strand breaks (DSBs) and collapsed replication forks by the process of homologous recombination (HR), and are therefore essential for maintaining genomic stability (6) . effect of BRCA1/BRCA2 mutation and interventional PARP-1 inhibition, leading to deficiency in both the SSB and DSB pathways, has been shown to enhance the cytotoxic effects of ionizing radiation and DNA damaging chemotherapy agents, such as DNA cross-linking agents, alkylating agents and topoisomerase I inhibitors (7) (8) (9) .
Most HGSC, regardless of the BRCA mutation status, have already spread beyond the confines of the ovary at diagnosis and therefore management involves surgical debulking followed by chemotherapy with carboplatin and a taxane (10, 11) . To improve response rates and treatment-free intervals and to offer treatment alternatives to these existing therapies, PARP inhibitors have been recently introduced and tested in early clinical trials as single agents or as part of combination therapies in patients with advanced solid tumors (12) (13) (14) . These trials were prompted by convincing pre-clinical assays showing that cell lines lacking wild-type BRCA1 or BRCA2 were extremely sensitive to potent PARP inhibitors compared with heterozygous mutant or wild-type cells (15) (16) (17) (18) .
Recently, the orally active PARP inhibitor, olaparib (AZD2281), was evaluated as a single agent therapy in humans demonstrating clinical anti-tumor activity in BRCAassociated cancers (primarily ovarian carcinomas) (14) .
In this study we present a BRCA2-mutated human ovarian cancer tissue explant xenograft model to investigate the therapeutic response to olaparib as a single agent and in combination with chemotherapy.
Materials and Methods
Research. 
BRCA mutation analysis
BRCA2 coding sequence mutations were confirmed by whole transcriptome RNA sequencing (RNA-seq) as previously described (20) and direct sequencing (ABI, 3130xl
Genetic Analyzer) in original patient tumour and in the later passages of tumour line LTL247 (primer sequences exon 11: BRCA2 forward aaagaccctaaagtacagagagg, BRCA2 reverse cggcccgccgcccccgcccgatttattctttctggttgaccatc). Wild-type status of BRCA 1 and 2 in LTL 258 were confirmed using reference primers as described before (4).
Research. analogous germline states, and neutral copy number.
Olaparib efficacy studies
The structure and activity of olaparib (AZD2281, KU-0059436) has been previously described (9, 14, 17, 18) . Olaparib was solubilized in DMSO and diluted to 5mg/mL with PBS containing 10%(w/v) 2-hydroxy-propyl-beta-cyclodextrin (Sigma). LTL247 and x5 weeks for LTL258 (18) . Mice were provided with food and water ad libitum and monitored daily for changes in general health, including body weight loss, diarrhea, food/water intake, appearance and behavior. Tumors were harvested on day 29 and 35 for LTL247 and LTL258, respectively, two hours after last dosing.
Tumor burden was determined at necropsy as previously described (19) . Mean tumour volume (mm 3 ) ± standard deviation (SD) was calculated and growth inhibition (GI) reported as the percentage decrease of tumor volume compared to the vehicle control. Individual group comparisons were performed using independent student t tests and overall group comparisons were performed using one-way ANOVA. Results with pvalues < 0.05 were reported as significant.
Immunohistochemistry (proliferation and apoptotic indices)
Immunohistochemistry was performed on 5 µm paraffin-embedded tissue sections using TUNEL assays (ApopTag® Apoptosis Detection Kit, Chemicon, Temecula, CA) and a monoclonal MIB1 antibody (Dako, Mississauga, ON, Canada, dilution 1:50) directed against the Ki-67 antigen as previously described (19) .
For cleaved caspase-3 staining, 4 µm thick sections were cut and immunostained on a Ventana Discovery XT staining system (Ventana Medical Systems, AZ, USA).
Sections were deparaffinized in xylene, dehydrated through three alcohol changes, and 
Compound level quantification and PARP-1 activity determination in BRCA2 -/-tumor tissues
To demonstrate the specific PARP inhibitory effect of olaparib therapy we determined the ex vivo PARP-1 activity in relation to the drug compound levels in five
BRCA2
-/-xenografts of LTL247after four weeks of treatment and six untreated controls.
Olaparib levels were analyzed by ultra performance liquid chromatographytandem mass spectrometry (UPLC-MS/MS). Tumors were weighed, homogenized in three volumes of PBS and samples extracted using solid phase extraction (SPE).
Chromatographic separation was by gradient elution using an Acquity BEH Phenyl Calibration standards (10ng/mL-5000ng/mL) and quality control samples were prepared in mouse plasma and tumour homogenate.
Research. PARP-1 activity within tumor samples was analyzed using an ex vivo activation assay as previously described (9) .
Results

Model characterization
We selected a tumor line originating from a patient with known heterozygous BRCA2 germline mutation. This mutation could be characterized as a two base pair deletion frame shift mutation in BRCA2 exon 11 using the patients constitutional DNA (peripheral blood) ( Figure 1 ). Copy number analysis of the patient tumor and the late generation xenograft revealed a hemizygous deletion of the BRCA2 locus with loss of heterozygosity. Accordingly, direct sequencing showed a homozygous state of the frameshift mutation in the primary and xenograft tumors. RNA-seq confirmed exclusive expression of the mutated allele that was supported by two reads (data not shown). In summary, this homozygous frameshift mutation can be considered a loss of function mutation. In contrast, tumor line LTL258 did not show BRCA1 or BRCA2 mutations (data not shown).
Olaparib inhibits growth of BRCA2-/-ovarian cancer tissue xenografts
All 39 mice included in the study were available for evaluation and measurement of tumors on harvest day. On macroscopic inspection, LTL247
BRCA2-/-xenografts treated for four weeks with vehicle showed, on average, markedly enlarged tumor masses.
This was confirmed on microscopic evaluation, with H&E staining identifying viable cancer cells (Figure 2, middle) . In contrast, olaparib-treated tumors showed much
Toxicity evaluation
Only four of all the treated animals showed substantial loss of body weight (>10%), 
Olaparib-treated tumors exhibit decreased proliferation and increased apoptosis
Immunohistochemical analysis of Ki-67-stained tissue sections from four Notably, the addition of the PARP-inhibitor to carboplatin did not increase toxicity in mice.
Research. genetically altered mouse models (17, 18) . In these studies the authors observed in vivo efficacy of olaparib (AZD2281) against BRCAassociated murine breast cancers with improvements in both recurrence-free and overall survival. We show, for the first time, that olaparib confers anti-tumor activity and improved survival in an experimental model utilizing human ovarian tumor tissue xenografts. Obvious differences between these models include variation of the genetic backgrounds across species, altered host immune responses, and the tissues studied.
However, the comparability of the results further supports the efficacy of olaparib in these models independent of these parameters.
PARP inhibitors are currently being tested in various phase I/II clinical trials (7) and another PARP-inhibitor compound (BSI-201) is being investigated in a phase III Furthermore, tumor relapse could be delayed in a mouse model by continuous treatment with olaparib alone after carboplatin chemotherapy suggesting a role for olaparib in maintenance therapy during remissions (17, 18) . It is possible that development of resistance to PARP inhibitors will hamper further clinical progress.
Therefore, model systems that allow for the study of drug resistance would be useful.
Here, we demonstrated that a human ovarian cancer tissue explant xenograft mouse model has utility for the testing of experimental drugs in BRCA-mutated tumors. In the future, development of additional tumour tissue lines, including those that progressed under treatment, has the potential to elucidate the underlying molecular mechanisms of olaparib drug resistance.
In conclusion, this study shows the applicability of a xenograft model for experimental 
